2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107710
    LY 233053 125546-04-5 98%
    LY 233053 is a potent and competitive NMDA-receptor antagonist with anticonvulsant and antiepileptic efficacy.
    LY 233053
  • HY-107716
    Ro 8-4304 hydrochloride 1312991-77-7 98%
    Ro 8-4304 hydrochloride is a potent NMDA receptor antagonist. Ro 8-4304 hydrochloride is a NR2B selective, non-competitive, voltage-independent antagonist.
    Ro 8-4304 hydrochloride
  • HY-107717
    MNI-caged-NMDA 1227675-52-6 98%
    MNI-caged-NMDA is a light-sensitive amino acid with rapid release properties suitable for use in the study of fast synaptic receptor mechanisms. MNI-caged-NMDA shows metered release of NMDA receptors, inducing rapid and sustained receptor activation in cerebellar interneurons. MNI-caged-NMDA is able to achieve rapid transient responses and generate large inward currents by local laser photolysis. The use of MNI-caged-NMDA can effectively study neurotransmitter signaling and its inhibitory effects on GABA-A receptors.
    MNI-caged-NMDA
  • HY-107718
    Midafotel 117414-74-1 99.00%
    Midafotel (SDZ-EAA 494) is a potent and comprtitive NMDA antagonist with an ED50 value of 39 nM. Midafotel causes intense stereotyped behaviors. Midafotel shows neuroprotective effects.
    Midafotel
  • HY-107727
    BMS-193885 L-Lactic acid 679839-66-8 98%
    BMS-193885 (L-Lactic acid) is a potent, selective, and brain-penetrant neuropeptide Y1 receptor antagonist. BMS-193885 has a Ki value of 3.3 nM for the neuropeptide Y1 receptor, competitively acts on the neuropeptide Y binding site, and can reduce food intake and body weight through central Y1 inhibition.
    BMS-193885 L-Lactic acid
  • HY-107745
    SDM25N hydrochloride 342884-71-3 98%
    SDM25N hydrochloride, a δ-opioid receptor antagonist, is a potent DENV inhibitor. SDM25N hydrochloride targets the viral NS4B protein and restricts genomic RNA replication.
    SDM25N hydrochloride
  • HY-107751
    BW373U86 155836-50-3 98%
    BW373U86 (SNC86) is a δ-opioid receptor agonist with an IC50 of 1.49 nM. BW373U86 shows antidepressant-like effects.
    BW373U86
  • HY-107756
    LOE 908 hydrochloride 143482-60-4 98%
    LOE 908 hydrochloride is a non-selective cation channel (NSCC) inhibitor.
    LOE 908 hydrochloride
  • HY-107761
    JMV 390-1 148473-36-3 98%
    JMV 390-1 (Compound 6a) is a potent multipeptidase inhibitor. JMV 390-1 behaves as a full inhibitor of the major neurotensin (NT)/neuromedin N (NN) degrading enzymes in vitro with IC50 values from 30 to 60 nM. JMV 390-1 increases endogenous recovery of NT and NN from slices of mice hypothalamus depolarized with potassium.
    JMV 390-1
  • HY-107803
    Geranium oil 8000-46-2 98%
    Geranium oil serves as a partial agonist for estrogen receptor (ER), enhancing both the cytotoxicity induced by Tamoxifen (TMX) (HY-13757A) in GT1-7 cells and the adverse effects of TMX on the central nervous system. Geranium oil can be utilized in the research of neurological disorders such as dementia.
    Geranium oil
  • HY-107805
    Dihydroactinidiolide 17092-92-1 98.10%
    Dihydroactinidiolide, existing in plant leaves and fruits, is a potent plant growth inhibitor, a regulator of gene expression and is responsible for photo acclimation in Arabidopsis. Dihydroactinidiolide has antioxidant activity, antibacterial activity, anticancer activity and neuroprotective effect. Dihydroactinidiolide is also an inhibitor of AChE (IC50=34.03 nM) and has scavenging activities for DPPH and (.NO). Dihydroactinidiolide is present in plant leaves and fruits and is a potent plant growth inhibitor, regulator of gene expression, and responsible for light adaptation in Arabidopsis.
    Dihydroactinidiolide
  • HY-107847
    2-(2-Methoxyphenoxy)ethylamine hydrochloride 64464-07-9 ≥98.0%
    2-(2-Methoxyphenoxy)ethylamine hydrochloride (Compound 2b) is a mixed agonist/antagonist. 2-(2-Methoxyphenoxy)ethylamine hydrochloride is a5-HT1A receptor partial agonist and a α1-adrenergic receptor antagonist. 2-(2-Methoxyphenoxy)ethylamine hydrochloride can be used for neurological diseases research, such as anxiety, depression and psychosis.
    2-(2-Methoxyphenoxy)ethylamine hydrochloride
  • HY-107947
    Fluphenazine enanthate 2746-81-8 98%
    Fluphenazine enanthate is a long-acting injectable (LAI) antipsychotic for the treatment of schizophrenia.
    Fluphenazine enanthate
  • HY-107956
    Imipramine pamoate 10075-24-8 98%
    Imipramine pamoate is a potent anti-depressant compound.
    Imipramine pamoate
  • HY-108030
    Bencycloquidium bromide 860804-18-8 98%
    Bencycloquidium bromide, a muscarinic M(3) receptor antagonist, is an anticholinergic compound that acts as an anticholinergic bronchodilator. Bencycloquidium bromide can be used in the study for rhinitis.
    Bencycloquidium bromide
  • HY-108035
    (-)-JM-1232 1013427-48-9 98%
    (-)-JM-1232 (MR04A3) targets GABA A receptors and exerts its analgesic effects by binding to the benzodiazepine binding site of GABA A receptors. (-)-JM-1232 demonstrates potent analgesic effects in mice against acute thermal stimuli, mechanically induced pain, and visceral pain, with CI50 values of 2.96, 3.06, and 2.27 mg/kg, respectively. (-)-JM-1232 can be used in research related to pain and analgesia.
    (-)-JM-1232
  • HY-108043
    AZD-2327 875647-81-7 98%
    AZD-2327 is a potent and selective δ-opioid receptor agonist. AZD-2327 binds to the human opioid receptor (Ki = 0.49 and 0.75 nM and EC50 = 24 and 9.2 nM at the C27 and F27 isoforms, respectively). AZD-2327 shows selectivity of >1000-fold over the human μ- and κ-opioid receptor subtypes as well as >130 other receptors and channels. AZD-2327 exhibits antidepressant and anxiolytic activities and can be used for the research of neurological disease.
    AZD-2327
  • HY-108048
    Desoxypeganine 495-59-0 98%
    Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective MAO-A inhibitor, with IC50 values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research.
    Desoxypeganine
  • HY-10805S
    Almorexant-13C,d3 98%
    Almorexant-13C,d3 is the 13C- and deuterium labeled Almorexant. Almorexant (ACT 078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM, respectively.
    Almorexant-13C,d3
  • HY-108071
    BTG-1675A 812639-72-8 98%
    BTG-1675A is a potential anti anxiety agent.
    BTG-1675A
Cat. No. Product Name / Synonyms Application Reactivity